NicOx successfully completes its right issue, raising €100 million following a two-step capital increase

23-Dec-2009 - France

NicOx S.A. announced that it has raised a total of approximately €100 million via a two-step capital increase. The second step of this capital increase was the completion of a rights issue, launched on November 25th 2009, which raised total gross proceeds of €69.9 million through the issuance of 20,042,031 new ordinary shares.

The proceeds from the two-step financing will support NicOx’s strategic goal of becoming a specialty pharmaceutical company with targeted specialty sales operations in the United States, allowing the Company to play a direct role in the commercialization of naproxcinod, and to generate additional shareholder value from its innovative research and development pipeline.

Eric Castaldi, Chief Financial Officer of NicOx, declared: “We are very pleased with the great success of this capital increase, thanks to the support from our shareholders and new investors. The €100 million we have raised from this two-step financing should allow NicOx to pursue its strategic goal of establishing a direct commercial presence in the United States.”

Total demand for the rights issue amounted to approximately €104 million, reflecting an oversubscription rate of 149%. The exercise of preferential subscription rights by irrevocable entitlement (souscription à titre irréductible) amounted to 18,578,755 shares, representing 92.7% of the new ordinary shares to be issued. Subscription on a reducible basis (souscription à titre réductible) represented a demand for 11,323,873 shares and was therefore partially allocated, through the issue of 1,463,276 new shares.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Moderna Launches New Venture Valera LLC for Infectious Diseases

In the heat of the wound - Smart bandage

In the heat of the wound - Smart bandage

Sartorius opens new Center of Excellence for bioanalytics in Ann Arbor - Manufacturing of instruments, consumables and reagents for cell and protein analysis

Sartorius opens new Center of Excellence for bioanalytics in Ann Arbor - Manufacturing of instruments, consumables and reagents for cell and protein analysis

CyBio and Macherey-Nagel collaborate to develop applications for automated DNA/RNA preparation

Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."

Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."

HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells

HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells

Closure of Astellas CNS research in Edinburgh

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Ac­cel­er­at­ing the pace of dis­cov­ery in sci­ence and in­dustry

New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Ac­cel­er­at­ing the pace of dis­cov­ery in sci­ence and in­dustry

Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease

Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!